WallStreetZenWallStreetZen

NASDAQ: ELEV
Elevation Oncology Inc Stock

$1.02-0.02 (-1.92%)
Updated Jan 27, 2023
ELEV Price
$1.02
Fair Value Price
$3.30
Market Cap
$23.77M
52 Week Low
$0.72
52 Week High
$5.20
P/E
-0.31x
P/B
0.35x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$85.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.66
Operating Cash Flow
-$77M
Beta
0.66
Next Earnings
Mar 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ELEV Overview

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, is developing cancer treatments for genomically defined patient populations. The company's lead program is seribantumab, in a Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology was incorporated in 2019 and is based in New York, NY.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELEV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ELEV ($1.02) is undervalued by 69.07% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ELEV ($1.02) is significantly undervalued by 69.07% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ELEV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELEV due diligence checks available for Premium users.

Be the first to know about important ELEV news, forecast changes, insider trades & much more!

ELEV News

Valuation

ELEV fair value

Fair Value of ELEV stock based on Discounted Cash Flow (DCF)
Price
$1.02
Fair Value
$3.30
Undervalued by
69.07%
ELEV ($1.02) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELEV ($1.02) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELEV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ELEV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.31x
Industry
12.89x
Market
23.59x

ELEV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.35x
Industry
5.18x
ELEV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ELEV's financial health

Profit margin

Revenue
$0.0
Net Income
-$38.8M
Profit Margin
0%
ELEV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$111.5M
Liabilities
$44.4M
Debt to equity
0.66
ELEV's short-term assets ($110.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELEV's short-term assets ($110.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELEV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$44.2M
Investing
$13.4M
Financing
$29.5M
ELEV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ELEV vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ELEV$23.77M-1.92%-0.31x0.35x
CMMB$23.97M-7.96%-0.98x0.54x
SQZ$24.09M-2.62%-0.30x0.35x
RNXT$24.11M+3.52%-2.70x2.96x
TFFP$24.11M-0.53%-0.69x1.34x

Elevation Oncology Stock FAQ

What is Elevation Oncology's quote symbol?

NASDAQ: ELEV) Elevation Oncology trades on the NASDAQ under the ticker symbol ELEV. Elevation Oncology stock quotes can also be displayed as NASDAQ: ELEV.

If you're new to stock investing, here's how to buy Elevation Oncology stock.

What is the 52 week high and low for Elevation Oncology (NASDAQ: ELEV)?

(NASDAQ: ELEV) Elevation Oncology's 52-week high was $5.20, and its 52-week low was $0.72. It is currently -80.38% from its 52-week high and 41.08% from its 52-week low.

How much is Elevation Oncology stock worth today?

(NASDAQ: ELEV) Elevation Oncology currently has 23,300,796 outstanding shares. With Elevation Oncology stock trading at $1.02 per share, the total value of Elevation Oncology stock (market capitalization) is $23.77M.

Elevation Oncology stock was originally listed at a price of $11.44 in Jun 25, 2021. If you had invested in Elevation Oncology stock at $11.44, your return over the last 1 years would have been -91.08%, for an annualized return of -91.08% (not including any dividends or dividend reinvestments).

How much is Elevation Oncology's stock price per share?

(NASDAQ: ELEV) Elevation Oncology stock price per share is $1.02 today (as of Jan 27, 2023).

What is Elevation Oncology's Market Cap?

(NASDAQ: ELEV) Elevation Oncology's market cap is $23.77M, as of Jan 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Elevation Oncology's market cap is calculated by multiplying ELEV's current stock price of $1.02 by ELEV's total outstanding shares of 23,300,796.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.